Sample Size Estimation -Replicate design- BE limits [Power / Sample Size]

posted by cakhatri – India, 2017-11-30 10:44 (2017 d 04:34 ago) – Posting: # 18024
Views: 15,127

Dear All,

I would like to know

1.What BE limits should be taken into consideration while estimating sample size for replicate design studies for USFDA & EMA.

Should it be 80-125% ? We normally use FARTSSIE

Why the Question

1. For a product with 51% ISCV (from a completed partial replicate study UKMHRA) by using FARTSSIE we arrived at different sample size for EMA

- Sample size estimated = 27 (80% Power, 95-105% T/R, Method C1, BE Limits 69.84 to 143.19%)
- Sample size estimated = 76 (80% Power, 95-105% T/R, No reference Scaled BE Limits-80-125%)

Which sample size should we consider for pivotal study


Complete thread:

UA Flag
 Admin contact
22,627 posts in 4,743 threads, 1,613 registered users;
19 visitors (0 registered, 19 guests [including 13 identified bots]).
Forum time: 16:19 CEST (Europe/Vienna)

Facts are meaningless. You could use facts to prove
anything that’s even remotely true!    Homer Simpson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz